Search

  • Home
  • About
  • Solutions

      • Hematopoietic Stem Cells (HSCs)

        • TRANS-HSC-CB-MNC
        • TRANS-HSC-PBCD34+
        • TRANS-HSC-CBCD34+
        • TRANS-HSC-PB-MNC
        • View Category >

      • Stromal Progenitor hMPS

        • TRANS-MSC
        • TRANSCHYMAL™ – DP
        • TRANSCHYMAL™ – UC
        • TRANSCHYMAL™ – AD
        • View Category >

      • Tumor Tissue Model

        • Human Tumour Tissue, Frozen

      • Reconstructed Tissue

        • TRANSKIN

      • Primary Cancer Cells

        • TRANS -TR-C
        • TRANS -TR-O
        • TRANS -TR-H&N
        • TRANS-TR-B
        • View Category >

      • Cruelty Free Workstation Solution

        • NeuroSAFE
        • CardioSIGHT
        • HepatoSIGHT
        • HeMOToX
        • View Category >
  • Communications
    • Media
    • Events
  • Blog
  • Contact
FDA no longer needs to require animal tests before human drug trials, We are an international end user assessed ethically compliant and technically competent HBS provider through Science Exchange platform
FDA no longer needs to require animal tests before human drug trials, We are an international end user assessed ethically compliant and technically competent HBS provider through Science Exchange platform
Transcell Transcell Transcell
  • Home
  • About
  • Solutions

      • Hematopoietic Stem Cells (HSCs)

        • TRANS-HSC-CB-MNC
        • TRANS-HSC-PBCD34+
        • TRANS-HSC-CBCD34+
        • TRANS-HSC-PB-MNC
        • View Category >

      • Stromal Progenitor hMPS

        • TRANS-MSC
        • TRANSCHYMAL™ – DP
        • TRANSCHYMAL™ – UC
        • TRANSCHYMAL™ – AD
        • View Category >

      • Tumor Tissue Model

        • Human Tumour Tissue, Frozen

      • Reconstructed Tissue

        • TRANSKIN

      • Primary Cancer Cells

        • TRANS -TR-C
        • TRANS -TR-O
        • TRANS -TR-H&N
        • TRANS-TR-B
        • View Category >

      • Cruelty Free Workstation Solution

        • NeuroSAFE
        • CardioSIGHT
        • HepatoSIGHT
        • HeMOToX
        • View Category >
  • Communications
    • Media
    • Events
  • Blog
  • Contact
Home > Uncategorized > TranstoxBio’s New Platform For Testing Covid-19 Vaccines and Drug Candidates

TranstoxBio’s New Platform For Testing Covid-19 Vaccines and Drug Candidates

June 30, 2020 transcell-admin
TranstoxBio’s New Platform For Testing Covid-19 hospitalharrywilliams.org

Vaccines and Drug Candidates.

June 30, 2020

News Update on Transcell Oncologics agoradesign.it Announces New Portfolio Transtoxbio Testing

Share:

Categories

  • Uncategorized

Related Posts

Animal Free Testing Strategy for Measuring Antivenom Potency
August 5, 2023 transcell-admin
PRIMATES – NO MORE A MODEL TO TEST VACCINES
August 31, 2020 transcell-admin
Transcell Oncologics brings unique portfolio for COVID-19 vaccines & drug candidates
June 19, 2020 transcell-admin
Biotech Express Transtoxbio Article
March 19, 2020 transcell-admin
News Update on Transcell Oncologics’s Cell Based Platforms Portfolio Onboarding Channel Partner For New Geographies
March 18, 2020 transcell-admin

info@transtoxbio.com

Contact US

Social Icons

  • Facebook
  • LinkedIn
  • Twitter
Need help

phone-icon 1-908-325-2508

phone-icon +91-77999-14445

Information
  • About us
  • Our Blog
  • Events
  • Media
  • Privacy Policy

Copyright © 2023 Transcell . All Rights Reserved

Back to Top
Product has been added to your cart
Close